arrow_back Back to App

Extended Expiration Dates for Lifesaving Drugs: Increased Access and Safety

This act aims to ensure that life-saving drugs remain available for longer periods by requiring manufacturers to test and confirm their longest possible expiration dates. This means less waste and greater assurance that necessary medications will be accessible, especially during crises or when shortages occur. Manufacturers who fail to comply with these rules may face financial penalties.
Key points
Manufacturers of life-saving drugs must test and submit data to determine the longest possible expiration dates for their products.
The act applies to critical emergency drugs, drugs on the shortage list, and those essential for life support or treating debilitating conditions.
It introduces financial penalties for manufacturers who fail to provide required data or update labels according to new guidelines.
The goal is to increase drug availability and reduce shortage risks, directly impacting citizens' health and safety.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_3793
Sponsor: Rep. Slotkin, Elissa [D-MI-7]
Process start date: 2023-06-05
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Ensuring Access to Lifesaving Drugs Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_3793.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-05.

What are the main provisions?

Key points include:

  • Manufacturers of life-saving drugs must test and submit data to determine the longest possible expiration dates for their products.
  • The act applies to critical emergency drugs, drugs on the shortage list, and those essential for life support or treating debilitating conditions.
  • It introduces financial penalties for manufacturers who fail to provide required data or update labels according to new guidelines.
  • The goal is to increase drug availability and reduce shortage risks, directly impacting citizens' health and safety.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Slotkin, Elissa [D-MI-7].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health